Minerva Neurosciences to Present at JMP Securities CNS Forum
Minerva Neurosciences, a clinical-stage biopharmaceutical firm focused on CNS disorders, will present at the JMP Securities CNS Forum on August 19, 2020, at 10:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Minerva Neurosciences, a clinical-stage biopharmaceutical firm focused on CNS disorders, will present at the JMP Securities CNS Forum on August 19, 2020, at 10:30 a.m. ET. This virtual event will be accessible via a webcast on the company's investor relations website. Minerva's product pipeline includes roluperidone for schizophrenia, seltorexant for insomnia and MDD, and MIN-301 for Parkinson's disease. The stock trades on NASDAQ under the symbol NERV.
Details
News Market Reaction – NERV
The recorded move for NERV in the trading session of this news was -2.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the JMP Securities CNS Forum on August 19, 2020 at 10:30 a.m. Eastern Time. This event will be held virtually.
The presentation will be webcast and accessible on a live and archived basis through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com.
About Minerva Neurosciences
Minerva’s portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia; a potential royalty stream from seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.